🧬 Tuhauora Thyroid Cancer ATA 2025 Advisor
Clinical Decision Support · 2025 American Thyroid Association DTC Guidelines · Ringel & Sosa et al., Thyroid 2025
⚠️ Clinical Decision Support Only. This tool applies the 2025 ATA DTC Guidelines to assist clinician reasoning. It does not replace clinician judgment, MDT review, local protocols, or patient-specific shared decision-making. Always verify recommendations against the source guideline.
👤 Patient Demographics
🔬 Histology & Diagnosis
📐 Tumour Characteristics (Pathological)
🔵 Nodal Status
🌐 Distant Metastases
🧪 Molecular Markers
Molecular markers refine risk stratification. BRAF V600E + TERT promoter co-mutation confers highest risk (Intermediate-High/High). Provide results where available.
🔪 Surgery
📊 Post-Treatment Biochemistry & Imaging (Dynamic Re-stratification)
Complete this section if surgery (±RAI) has been performed to apply response-to-therapy re-stratification (Table 9, ATA 2025).
Complete patient data and click Generate Clinical Analysis to view results.
Generate a clinical analysis first to view the 5-year surveillance plan.
Generate a clinical analysis first to view the MDT/EMR summary.
Generate a clinical analysis first to view the patient summary.
Contact
Business Hours: 9am- 5pm
Consulting days: Monday, Tuesday, Wednesday
09 553 3781
EDI: entnorth
Visit us
Inside the Allevia Kensington Hospital reception area.
12 Kensington Ave Whangarei
